YYYuto Yasui

Yuto Yasui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuto Yasui has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Virus Detection in Pediatric Patients Hospitalized with Respiratory Tract Infections Using Quantitative Multiplex PCR

    by Yuto Yasui, Tomohiro Oishi, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    Respiratory tract infections (RTIs) are common in children. Viruses are known to be related to most pediatric infections. However, some pediatric cases of RTI have been found to be associated with multiple viruses. In this study, we collected samples from the nasopharynx of all pediatric patients admitted to our hospital with RTI between April 2022 and March 2023 and performed multiple quantitative real-time PCRs. Out of 77 patients involved, 67 (87.0%) tested positive for some or the other virus. Rhinovirus was the most detected, followed by the RS virus and parainfluenza virus type 3. Among the patients, 18 (26.9%) had multiple viral infections and 14 had complications associated with obstructive respiratory diseases, including bronchial asthma, acute bronchiolitis, and asthmatic bronchitis. Furthermore, some cases were found to have both the main and non-main viruses. Multiple viruses were detected in approximately one-fourth of the children with RTIs; complications associated with obstructive respiratory diseases were considered to be the main factors.

  • Open Access

    Evaluation of Neutralizing Antibodies on Respiratory Syncytial Virus in Japanese Mother-Infant Pairs after COVID-19 Pandemic

    by Tomohiro Oishi, Daisuke Yoshioka, Sachie Ono, Yuto Yasui, Atsushi Kato, Satoko Ogita, Tomoaki Tokutomi, Mazumi Miura, Takahiro Eitoku, Hideo Enoki, et al.

    Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection in young children globally. Following the COVID-19 pandemic, RSV infections have become more prevalent. Consequently, a new vaccine targeting RSV infections in pregnant women has been introduced worldwide. To estimate the effectiveness of this new vaccine for pregnant women, we investigated neutralizing antibodies against RSV in samples taken from 51 mothers and their babies. The prevalence rate of neonatal antibodies, defined as a titer of ≥16, was 39.2%. We found no significant differences in neonatal neutralizing antibodies based on factors, such as sex, gestational age at birth, birth weight, presence of siblings, neonatal problem, and usage of palivizumab. Neonatal neutralizing antibodies were equal to or higher than those of their mother. A new RSV vaccine targeting all pregnant women is promising, as approximately 60% of neonates had low antibody titers against RSV. However, predicting low antibody titer against RSV remains challenging. Moreover, our findings indicate efficient transmission of RSV antibodies from babies to their mothers.

  • Open Access

    Analysis of Cell Immunity for Children Infected with SARS-CoV-2 and Those Vaccinated against SARS-CoV-2 Using T-SPOT®.COVID

    by Tomohiro Oishi, Yuto Yasui, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    Cellular immunity is critical for the regulation of viral diseases, including coronavirus disease 2019 (COVID-19), and is generally considered immature in childhood. However, the details of cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among children are unclear. We assessed cellular immunity in eight children post-vaccination against SARS-CoV-2 and 11 children after SARS-CoV-2 infection using the T-SPOT®.COVID assay for the spike (S) and nucleocapsid (N) proteins. In the vaccinated group, the T-SPOT®.COVID assay for the S protein yielded positive results in seven children. In the post-infection group, the assay for the N protein was positive for 5 of 11 children, with 3 of these 5 children requiring hospitalization, including 2 who needed mechanical ventilation. The T-SPOT®.COVID assay is thus valuable for assessing cellular immunity against SARS-CoV-2, and most children infected with SARS-CoV-2 may not develop such immunity unless the disease severity is significant.


  • Open Access

    Analysis of Cell Immunity for Children Infected with COVID-19 and Those Vaccinated against COVID-19 Using T-SPOT®.COVID

    by Tomohiro Oishi, Yuto Yasui, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    To elucidate the cellular immune response to coronavirus disease (COVID-19) among children, we assessed cellular immunity in 8 children post-vaccination for COVID-19 and 11 children after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, using the T-SPOT®.COVID assay for both the spike (S) and nucleocapsid (N) proteins. In the vaccinated group, the T-SPOT®.COVID assay for the S protein yielded positive results in all eight children. In contrast, in the post-infection group, the assay for the N protein was positive in 5 of 11 children, with 3 of these 5 children requiring hospital admission, including 2 who needed mechanical ventilation. Therefore, the T-SPOT®.COVID assay is valuable for assessing cellular immunity against COVID-19, and most children infected with COVID-19 may not develop such immunity unless the disease severity is significant.